Human Genome Epidemiology Literature Finder
Pharmacogenomics
Records 1 - 30 (of 406 Records) |
Query Trace: Tamoxifen[original query] |
---|
Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World journal of clinical oncology 2022 9 13 (8): 712-724. Tan Ern-Yu, Bharwani Lavina, Chia Yee-Hong, Soong Richie C T, Lee Sherylyn S Y, Chen Juliana J C, Chan Patrick M |
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Sep 28 (18): 4112-4120. Singer Christian F, , Holst Frederik, Steurer Stefan, Burandt Eike C, Lax Sigurd F, Jakesz Raimund, Rudas Margaretha, Stöger Herbert, Greil Richard, , Sauter Guido, Filipits Martin, , Simon Ronald, Gnant Michael, |
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast cancer research and treatment 2022 Aug . Nemati Shafaee Maryam, Goutsouliak Kristina, Lin Heather, Bevers Therese B, Gutierrez-Barrera Angelica, Bondy Melissa, Arun Ba |
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 7 35 (12): 1804-1811. Grote Isabel, Bartels Stephan, Christgen Henriette, Radner Martin, Gronewold Malte, Kandt Leonie, Raap Mieke, Lehmann Ulrich, Gluz Oleg, Graeser Monika, Kuemmel Sherko, Nitz Ulrike, Harbeck Nadia, Kreipe Hans, Christgen Matthi |
(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. Journal of personalized medicine 2022 4 12 (4): . Almeida Thais, Schroth Werner, Nardin Jeanine, Mürdter Thomas E, Winter Stefan, Picolotto Solane, Hoppe Reiner, Kogin Jenifer, Gaio Elisa, Dasenbrock Angela, Skrsypcsak Raquel Cristina, de Noronha Lucia, Schwab Matthias, Brauch Hiltrud, Casali-da-Rocha José Claud |
Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant. BMC research notes 2022 3 15 (1): 104. Ranadeva Nadeeka Dimuthu Kumari, Sirisena Nirmala Dushyanthi, Wetthasinghe Tithila Kalum, Noordeen Nafeesa, Dissanayake Vajira Harshadeva Weerabadda |
Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients. Biochemical genetics 2022 Feb . Allahloubi Nasr M A, Zekri Abdel-Rahman N, Ragab Mohamed, Mohanad Marwa, Ahmed Ola S, Eid Salem, Ghareeb Mohamed, Gouda Iman, Bahnassy Abeer |
CYP2C19*17 association with higher plasma 4-hydroxy tamoxifen in Pakistani (estrogen-positive) breast cancer patients. Experimental biology and medicine (Maywood, N.J.) 2023 9 15353702231187640. Muhammad Usman Tareen, Sana Riaz, Saima Shakil Malik, Sana Zahid, Anum Khursheed, Fizza Tariq, Faiza Abbas, Muhammad Nouman Malik, Riffat Aysha Anis, Mariam Anees, Iram Murtaza, Aneesa Sult |
21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer. International journal of cancer 2023 9 . Jaewon Hyung, Sae Byul Lee, Jisun Kim, Hee Jeong Kim, BeomSeok Ko, Jong Won Lee, Byung-Ho Son, Hee Jin Lee, Gyungyub Gong, Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae K |
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). BMC cancer 2023 9 23 (1): 865. Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, Yasuaki Sagara, Yuan-Ching Chang, Hsien-Tang Yeh, Yao-Lung Kuo, Chih-Chiang Hung, Tzu-Pin Lu, Yi-Hsuan Lee, Masakazu Toi, Chiun-Sheng Hua |
Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer research and treatment 2023 8 . Xin Li, Zehao Li, Lin Li, Tong Liu, Cheng Qian, Yanlv Ren, Zhigao Li, Kejin Chen, Dongchen Ji, Ming Zhang, Jinsong Wa |
Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug metabolism and personalized therapy 2023 7 . Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko, Mikhail Vitalyevich Ily |
EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker. Archives of medical research 2023 7 102852. Nisha Gautam, Satbir Kaur, Surender Kashy |
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast cancer research and treatment 2023 7 . Joanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, Amber Aeilts, Susan Randall Armel, Beth Karlan, Christian F Singer, Andrea Eisen, Nadine Tung, Olufunmilayo Olopade, Louise Bordeleau, Charis Eng, William D Foulkes, Susan L Neuhausen, Carey A Cullinane, Tuya Pal, Robert Fruscio, Jan Lubinski, Kelly Metcalfe, Ping Sun, Steven A Narod, |
Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy. Radiology and oncology 2023 6 57 (2): 220-228. Domen Ribnikar, Valentina Jeric Horvat, Ivica Ratosa, Zachary W Veitch, Biljana Grcar Kuzmanov, Srdjan Novakovic, Erik Langerholc, Eitan Amir, Bostjan Seru |
Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British journal of clinical pharmacology 2023 6 . Bianza Tinotenda Mbavha, Roslyn Stella Thelingwani, Zedias Chikwambi, Anna Mary Nyakabau, Collen Masimirembwa, |
Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis. Breast (Edinburgh, Scotland) 2023 4 69 342-348. Blancas Isabel, Linares-Rodríguez Marina, Martínez de Dueñas Eduardo, Herrero-Vicent Carmen, Molero-Mir María D, Garrido José M, Rodríguez-Serrano Fernan |
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer. Breast cancer research and treatment 2023 4 . Souwer E T D, Sanchez-Spitman A, Moes D J A R, Gelderblom H, Swen J J, Portielje J E A, Guchelaar H J, van Gelder |
Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. Breast cancer research and treatment 2023 3 . Thorén Linda, Margolin Sara, Eliasson Erik, Bergh Jonas, Lindh Jonatan |
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 2 160 114369. Agema Bram C, Buijs Sanne M, Sassen Sebastiaan D T, Mürdter Thomas E, Schwab Mathias, Koch Birgit C P, Jager Agnes, van Schaik Ron H N, Mathijssen Ron H J, Koolen Stijn L |
Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. Journal of personalized medicine 2023 2 13 (2): . Kanji Comfort Ropafadzo, Nyabadza Georginah, Nhachi Charles, Masimirembwa Coll |
Novel independent trans- and cis-genetic variants associated with CYP2D6 expression and activity in human livers. Drug metabolism and disposition: the biological fate of chemicals 2023 12 . Dylan Smith, Bing He, Jian Shi, Hao-Jie Zhu, Xinwen Wa |
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network. Aging 2023 12 15 . Hongyan Qian, Rui Ji, Cheng Shen, Yinze Wei, Chenyi Sheng, Qichao Ni, Jing Pan, Yifan Chi, Huan You, Ying Miao, Minxin Shi, Xianghua Huang, Aiguo Sh |
Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer. Journal of pharmaceutical and biomedical analysis 2023 11 238 115839. Fatemeh Saghafi, Ebrahim Salehifar, Pouneh Ebrahimi, Mohammad Reza Shiran, Ehsan Zaboli, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh, Amirhossein Sahebk |
CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients. Personalized medicine 2023 11 . Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esper |
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 10 . Benedetta Conte, Luca Boni, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Maria De Angioletti, Anna Turletti, Mauro Mansutti, Fabio Puglisi, Antonio Frassoldati, Mauro Porpiglia, Alessandra Fabi, Daniele Generali, Giovanni Scognamiglio, Maura Rossi, Fara Brasó Maristany, Aleix Prat, Barbara Cardinali, Patrizia Piccioli, Martina Serra, Sonia Lastraioli, Claudia Bighin, Francesca Poggio, Matteo Lambertini, Lucia Del Mast |
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 2023 1 19 (1): e1010563. Ferrando Lorenzo, Vingiani Andrea, Garuti Anna, Vernieri Claudio, Belfiore Antonino, Agnelli Luca, Dagrada Gianpaolo, Ivanoiu Diana, Bonizzi Giuseppina, Munzone Elisabetta, Lippolis Luana, Dameri Martina, Ravera Francesco, Colleoni Marco, Viale Giuseppe, Magnani Luca, Ballestrero Alberto, Zoppoli Gabriele, Pruneri Giancar |
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Clinical pharmacology and therapeutics 2023 1 113 (3): 712-723. Khor Chiea Chuen, Winter Stefan, Sutiman Natalia, Mürdter Thomas E, Chen Sylvia, Lim Joanne Siok Liu, Li Zheng, Li Jingmei, Sim Kar Seng, Ganchev Boian, Eccles Diana, Eccles Bryony, Tapper William, Zgheib Nathalie K, Tfayli Arafat, Ng Raymond Chee Hui, Yap Yoon Sim, Lim Elaine, Wong Mabel, Wong Nan Soon, Ang Peter Cher Siang, Dent Rebecca, Tremmel Roman, Klein Kathrin, Schaeffeler Elke, Zhou Yitian, Lauschke Volker M, Eichelbaum Michel, Schwab Matthias, Brauch Hiltrud B, Chowbay Balram, Schroth Wern |
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations. Cancer chemotherapy and pharmacology 2024 2 . Xiaoya Ma, Yujie Li, Xufeng Zang, Jinping Guo, Wenqian Zhou, Junhui Han, Jing Liang, Panpan Wan, Hua Yang, Tianbo J |
Risk factors for male breast cancer. American journal of translational research 2024 1 15 (12): 6918-6925. Ian S Fentim |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: